Last updated: July 25, 2026
METACEL PHARMACEUTICALS LLC v. RUBICON RESEARCH LIMITED (2:21-cv-19463) litigation summary: claims, posture, and what it signals for IP enforcement
METACEL PHARMACEUTICALS LLC sued RUBICON RESEARCH LIMITED in the District of New Jersey in 2021 under case number 2:21-cv-19463. The available record in the public case caption confirms the parties and jurisdiction, but no litigation merits details (asserted patents, claim construction, dispositive motion outcomes, settlement terms, or final judgment) are provided in the information available here. Without those case-specific filings or docket outcomes, a complete and accurate litigation summary cannot be produced.
Result: No analysis can be stated from the limited identifier alone.
What patents are asserted in METACEL PHARMACEUTICALS LLC v. RUBICON RESEARCH LIMITED (2:21-cv-19463)?
No asserted-patent numbers, titles, or claims can be provided based on the case identifier alone.
Is this an ANDA/Biologics-type patent case or a trade secret/IP suit?
The nature of the claims (Patent Act, trade secret, contract, or other IP) is not stated in the information available.
Which jurisdictions and courts are involved beyond D.N.J.?
Only the D.N.J. docket identifier is known from the provided case number; no transfer, related actions, or additional fora are available.
What is the litigation posture for 2:21-cv-19463: motions, discovery, trial schedule?
A docket-stage posture cannot be derived without access to specific procedural entries (Rule 12 motions, claim construction schedule, discovery orders, or trial dates).
Were any dispositive motions decided?
No motion outcomes are available in the provided information.
Did the case proceed to summary judgment or trial?
No verdict, judgment, or trial disposition is available in the provided information.
How strong are METACEL’s claims based on the pleadings in 2:21-cv-19463?
Claim strength requires details: asserted independent claims, accused products/processes, and legal theories. None are available here.
What infringement theories are pleaded (literal infringement vs doctrine of equivalents)?
Not provided.
What defenses are raised (invalidity, non-infringement, unenforceability, estoppel)?
Not provided.
What patent defenses and invalidity arguments are implicated in 2:21-cv-19463?
Invalidity and enforceability analysis requires: prior art references, IPR status, USPTO proceedings, and claim-chart content. None are available.
Are there related IPRs or PTAB challenges?
Not provided.
Were any patents declared invalid or narrowed in prior proceedings?
Not provided.
What does the case outcome mean for generic or biosimilar entry risk against RUBICON?
Entry risk analysis depends on whether the case is tied to an FDA submission (ANDA/BLA), whether a 35 U.S.C. § 271(e)(2) claim exists, and whether there was a settlement or launch-triggered injunction. None of that is available.
Is there a Paragraph IV notice or Orange Book tether?
Not provided.
Did any settlement or consent judgment restrict launch dates?
Not provided.
Are there settlement agreements or licensing terms disclosed in 2:21-cv-19463?
No settlement terms, consent judgments, or licensing agreements are available in the information provided.
Did the parties agree to a stipulation of dismissal?
Not provided.
Timeline for 2:21-cv-19463: from filing to disposition
Only the case number and year of filing (2021) are inferable from the identifier. No procedural dates are available for a litigation timeline.
Key dates that typically matter (not available)
- Complaint filed date
- Service and responsive pleading dates
- Claim construction hearing
- Summary judgment motions
- Trial or dismissal date
- Any appeal and appellate docket numbers
Competitive and commercial impact: what products are implicated by this litigation?
Product-level impact requires identification of the accused rubicon product (API, formulation, device, or manufacturing method) and the commercial target (drug/indication and dosage form). None is provided.
What is the commercial scope (pipeline vs market) in 2:21-cv-19463?
Not provided.
How does METACEL’s enforcement strategy in 2:21-cv-19463 compare with other METACEL vs counterparties suits?
Comparison requires knowledge of other dockets, asserted patents, outcomes, and common themes. Not available.
Key Takeaways
- The case identifier confirms METACEL PHARMACEUTICALS LLC v. RUBICON RESEARCH LIMITED in the District of New Jersey (2:21-cv-19463).
- The information provided does not include asserted patents, factual allegations, procedural history, motion outcomes, settlement terms, or final disposition.
- A complete and accurate litigation summary and merits analysis cannot be stated from the case number alone.
FAQs
-
What does “2:21-cv-19463” tell you about the court and filing year?
It indicates a federal district-court case in 2021 in the District of New Jersey, but it does not specify the asserted claims or outcome.
-
How do I determine which patents were asserted in the complaint?
That requires the complaint document or docket entries listing asserted patent numbers, which are not available in the provided information.
-
What docket entries would show whether METACEL won or lost?
Dismissal orders, summary judgment rulings, trial judgments, or appellate dispositions, none of which are included here.
-
Does this kind of case automatically affect FDA approval timelines?
Only certain patent cases tether to FDA submissions under 35 U.S.C. § 271(e)(2). The claim type is not available here.
-
Can this litigation indicate whether RUBICON’s product was enjoined?
Injunction or consent judgment details are required; they are not provided.
References
- Public case caption provided in prompt: METACEL PHARMACEUTICALS LLC v. RUBICON RESEARCH LIMITED, 2:21-cv-19463 (D.N.J.).
